Prokidney (PROK) Revenue (2024 - 2026)

Prokidney (PROK) reported Revenue of $226000.0 for Q1 2026, down 1.74% year-over-year from $230000.0 in Q1 2025, and little changed on a QoQ basis from $225000.0 in Q4 2025.

Prokidney (PROK) has 3 years of Revenue data on file, last reported at $226000.0 in Q1 2026.

  • Quarterly Revenue fell 1.74% year-over-year to $226000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $889000.0 (up 190.52% YoY) and the FY2025 annual result came in at $893000.0, up 1075.0% from the prior year.
  • Revenue held at $226000.0 in Q1 2026 per PROK's latest filing, from $225000.0 in the prior quarter.
  • Across five years, Revenue topped out at $230000.0 in Q1 2025 and bottomed at $76000.0 in Q4 2024.
  • The 3-year median for Revenue is $223000.0 (2025), against an average of $199166.7.
  • The widest annual swing landed in 2025, when Revenue soared 196.05%; it then declined 1.74% in 2026.
  • Tracing PROK's Revenue over 3 years: stood at $76000.0 in 2024, then surged by 196.05% to $225000.0 in 2025, then gained by 0.44% to $226000.0 in 2026.
  • Per Business Quant, the three latest PROK Revenue figures stand at $226000.0 (Q1 2026), $225000.0 (Q4 2025), and $217000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 306.30 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 2.99 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 3.61 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.17 Bn
10 Prokidney 259.72 Mn 1.55 Bn - 226,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 226,000.00
Dec 31, 2025 225,000.00
Sep 30, 2025 217,000.00
Jun 30, 2025 221,000.00
Mar 31, 2025 230,000.00
Dec 31, 2024 76,000.00